#United States #New York #Securities #REGENXBIO #RGNX

Overview of the REGENXBIO Lawsuit

The Rosen Law Firm, a well-known global investor rights law firm, has issued a reminder to all purchasers of REGENXBIO, Inc. (NASDAQ: RGNX) securities. This reminder is particularly relevant for those who bought shares during the class period from February 9, 2022, to January 27, 2026. The firm highlights that investors have the opportunity to lead a securities fraud lawsuit against the company.

Important Deadlines

One key aspect to note for potential claimants is the upcoming deadline for lead plaintiffs, which is set for April 14, 2026. This deadline is vital for any investor wishing to take on the role of lead plaintiff, which involves representing the interests of other investors involved in the class action.

Potential for Compensation

Investors who purchased REGENXBIO securities during the specified class period may be entitled to compensation without any obligation to pay out-of-pocket fees, thanks to a contingency fee arrangement. Those wishing to join the class action can do so by visiting the Rosen Law Firm’s website or contacting the firm directly through phone or email.

Significance of Choosing the Right Law Firm

Choosing a qualified legal team is critical in securities class action cases. Rosen Law Firm stresses the importance of selecting a law firm with a solid track record in handling such cases. They highlight that many other firms sending out notices may lack the experience or resources necessary for effective representation, often serving only as intermediaries.

Background of REGENXBIO

The lawsuit alleges that the defendants provided investors with misleading information regarding REGENXBIO's plans for developing a gene therapy candidate known as RGX-111. This one-time treatment aims to address severe cases of Mucopolysaccharidosis Type I, also referred to as Hurler syndrome. Allegedly, the statements made by the company portrayed RGX-111 in an overly positive light, citing favorable safety and biomarker data from an ongoing study.

Factual Misrepresentation

However, the reality may be contrary to these claims, with the lawsuit suggesting that while REGENXBIO made bold assertions about the trial's success, it simultaneously withheld material adverse facts that could impact the efficacy and safety perceptions of RGX-111. The discrepancy in sharing this critical information led to significant damages for investors once the truth became publicly known.

How to Join the Class Action

To participate in the REGENXBIO class action, potential class members can easily navigate to the provided link on the Rosen Law Firm's website to submit their information. For any inquiries, Phillip Kim, Esq. from the firm is available for contact to discuss details regarding becoming a lead plaintiff or any other questions related to the lawsuit.

No Class Certified Yet

As of now, it is important to note that no class has been officially certified. This means investors are not represented by counsel unless they retain legal representation. Potential class members have the option to remain uninvolved and not take any action at this time, as participation in any future recovery is not contingent upon leading the class action.

Keeping Updated

Investors interested in ongoing updates regarding the REGENXBIO securities fraud lawsuit can follow the Rosen Law Firm on various social media platforms, including LinkedIn, Twitter, and Facebook.

In conclusion, investors of REGENXBIO have a timely opportunity to engage in a class action lawsuit which could lead to significant recoveries if the claims are substantiated. With a strong legal team backing, those affected can take decisive steps to safeguard their interests against alleged malpractices in securities dealings.